Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 21/9/2022 The Proposed issue is: A placement or other type of issue

Announcement Summary

ALTERITY THERAPEUTICS LIMITED

Date of this announcement

The Proposed issue is:

placement or other type of issue

Total number of +securities proposed to be issued for

a placement or other type of issue

Proposed +issue date

Refer to next page for full details of the announcement

- Entity and announcement details

ALTERITY THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information

about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement

basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure

document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under

the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final

number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete

and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

- Details of proposed placement or other issue

7A.1 Do any external approvals need to be obtained

or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Details of +securities proposed to be issued

ASX +security code and description

ATH : ORDINARY FULLY PAID

Number of +securities proposed to be issued

Are the +securities proposed to be issued being issued

for a cash consideration?

Will these +securities rank equally in all respects

from their issue date with the existing issued +securities in that class?

Proposed +issue date

7D - Listing Rule requirements

Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing

( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity

under listing rule 7.1?

Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement

capacity under listing rule 7.1A (if applicable)?

Is a party referred to in listing rule 10.11 participating in the proposed issue?

Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

Will any of the +securities to be issued be subject to +voluntary escrow?

7E - Fees and expenses

Will there be a lead manager or broker to the proposed issue?

Is the proposed issue to be underwritten?

Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

7F - Further Information

The purpose(s) for which the entity is issuing the securities

further research and development activities and provide on-going working capital.

Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

Any other information the entity wishes to provide about the proposed issue

Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions

in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)